This study investigated absorption of @entity5198 ( @entity16333 ) from targeted sites of the gastrointestinal tract using remotely activated capsules and gamma scintigraphy. A total of 24 @entity1 were randomized to receive 50 mg @entity16333 orally as a suspension or via remotely activated capsules for release into the ascending colon. The 24 @entity1 were then rerandomized into parallel groups of n = 8 for drug release into the ileum, jejunum, or descending colon. The mean gastric emptying time of capsules ranged from 0.88 to 3.35 hours. The small intestinal and colon transit time ranged from 4.08 to 7.76 hours and 17.6 to 21.2 hours, respectively, and capsule recovery time ranged from 27.6 to 34.4 hours. The relative bioavailability ratio of @entity16333 in the jejunum was 1.06 (90% confidence interval [CI]: 1.00-1.12) compared to suspension. In the ileum, ascending colon, and descending colon, bioavailability decreased to 0.89 (0.80-0.99), 0.82 (0.71-0.95), and 0.58 (0.22-1.53), respectively. The absorption rate decreased by approximately 10-fold from the jejunum (3.83 h(-1)) to the descending colon (0.338 h(-1)), and t(max) increased from 2.42 hours (jejunum) to 16.3 hours (descending colon). Overall, @entity16333 is absorbed from all 4 sites of the gastrointestinal tract, and the rate of absorption decreased from the jejunum to the descending colon. Relative bioavailability of @entity16333 was in the order of jejunum > ileum > ascending colon > descending colon.

Assessment of XXXX bioavailability from targeted sites in the @entity1 gastrointestinal tract.

@entity1 :: ('9606', 'Species') :: ['participants'] @entity16333 :: ('CHEBI:63613', 'Chemical') :: ['NVP'] @entity5198 :: ('MESH:D019829', 'Chemical') :: ['nevirapine']
@entity5198 :: (MESH:D019829,Chemical) :: ['nevirapine']
